These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 28411207)

  • 1. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
    Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
    Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
    Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
    Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 8. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
    Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
    Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Akamatsu S; Inoue T; Ogawa O; Gleave ME
    Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.
    Faugeroux V; Pailler E; Oulhen M; Deas O; Brulle-Soumare L; Hervieu C; Marty V; Alexandrova K; Andree KC; Stoecklein NH; Tramalloni D; Cairo S; NgoCamus M; Nicotra C; Terstappen LWMM; Manaresi N; Lapierre V; Fizazi K; Scoazec JY; Loriot Y; Judde JG; Farace F
    Nat Commun; 2020 Apr; 11(1):1884. PubMed ID: 32313004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
    Beltran H; Antonarakis ES; Morris MJ; Attard G
    Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
    Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
    Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
    Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging Variants of Castration-Resistant Prostate Cancer.
    Vlachostergios PJ; Puca L; Beltran H
    Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.